Long noncoding RNA associated with lymph node metastasis in cervical cancer (LNMICC) (LNMICC)

LNMICC (Long noncoding RNA associated with lymph node metastasis in cervical cancer) is a long noncoding RNA (lncRNA) overexpressed in cervical cancer cells with lymph node metastasis and is associated with poor patient survival[1]. LNMICC promotes lymph node metastasis by reprogramming fatty acid metabolism, specifically by recruiting nucleophosmin (NPM1) to the promoter of the fatty acid binding protein FABP5. This leads to enhanced cancer cell migration and invasion. The oncogenic effects of LNMICC can be suppressed by microRNA miR-190, highlighting a regulatory axis that might be therapeutically targetable. LNMICC functions as both a candidate therapeutic target and a prognostic biomarker for metastatic cervical cancer[1]. Note: LNMICC is a lncRNA, not a protein-coding gene, enzyme, or receptor, and is experimentally characterized as a regulator of metastasis rather than a conventional drug target. No approved drugs currently target LNMICC directly, and mechanistic drug interaction information is not available. There are no widely recognized aliases or alternative names for this lncRNA at this time[1]. Supporting detail: - LNMICC is confirmed as the major lncRNA associated with lymph node metastasis in cervical cancer, playing a key role in promoting metastasis and serving as an independent risk factor in patient survival[1]. - Its molecular function is to regulate gene expression involved in fatty acid metabolism, specifically by interacting with NPM1 and influencing FABP5 expression[1]. - While lncRNAs are emerging targets for therapy, clinical translation faces significant challenges, including specificity and delivery[1].